非小细胞肺癌组织中TC-1、CyclinD1、β-catenin蛋白表达的变化及意义  

Change of expression of TC-1,CyclinD1 and β-catenin in non-small cell lung cancer and its meaning

作　　者：罗建奎 邢时云[2] 

机构地区：[1]重庆市南川区结核病防治所,重庆南川408400 [2]遵义医学院附属医院胸部肿瘤科,贵州遵义463003

出　　处：《国际检验医学杂志》2014年第20期2723-2725,共3页International Journal of Laboratory Medicine

摘　　要：目的探讨甲状腺癌相关基因1(TC-1)、细胞周期蛋白D1(CyclinD1)、β-链蛋白(β-catenin)在非小细胞肺癌组织中的表达情况及其与非小细胞肺癌(NSCLC)病理特征的相关性。分析其与Wnt/β-catenin信号通路的调控的相关性,为研究TC-1在NSCLC中的作用提供依据。方法用免疫组化方法检测TC-1、CyclinD1、β-catenin蛋白在48例NSCLC中的表达,并结合肺癌的临床病理特征进行分析。结果 TC-1、CyclinD1、β-catenin在非小细胞肺癌组织中的表达水平明显高于正常肺组织;其中TC-1在NSCLC组织中的表达与淋巴结转移和TNM分期有关;β-catenin在NSCLC组织中的表达与病理类型和组织分化程度有关。结论 NSCLC患者中TC-1、CyclinD1和β-catenin蛋白的表达均为上调趋势,其可能在肺癌的发展中发挥重要作用;TC-1可能参与Wnt/β-catenin信号通路的调控作用,这些都为NSCLC的靶向治疗提供了新的研究思路。Objective To investigate the expression situation of thyroid cancer related gene-1 （TC-1）,CyclinD1 andβ-catenin in the tissues of non-small cell lung cancer（NSCLC）and their relationship with the clinical pathologic characteristics,to analyze their relationship with the regulation of Wnt/β-catenin signal pathway to provide the basis for studying the role of TC-1 in NSCLC. Methods The expressions of TC-1,CyclinD1 and β-catenin in 48 patients with NSCLC were detected by immunohistochemical SP method and analyzed by combining the clinical pathological features.Results The expression levels of TC-1,CyclinD1 andβ-catenin in the NSCLC tissue were significantly higher than those in the normal lung tissue;in which,the expression of TC-1 in NSCLC tis-sue was associated with lymph node metastasis and TNM stages;the expression ofβ-catenin in NSCLC tissue was related with the pathological types and tissue differentiation degree.Conclusion The expressions of TC-1,CyclinD1 andβ-catenin show the up-regu-lating trend in NSCLC and may play an important role in the development of lung cancer;TC-1 may be involved in the regulation of Wnt/β-catenin signaling pathway,which provide the new research thought of the NSCLC targeted therapy.

关 键 词：非小细胞肺癌 甲状腺癌相关基因1 细胞周期蛋白D1 Β-链蛋白 

分 类 号：R734.2[医药卫生—肿瘤]